BRAF and Miyoshi myopathy: The aims of this study were to characterize the pharmacokinetic variability of DAB, OHD, and TRA in a “real life” cohort of BRAF-mutated patients, then to investigate a potential exposure–response relationship for toxicity and efficacy in BRAF-mutated MM patients treated with DAB plus TRA.